Brief: AXIM Biotechnologies To Acquire Technology Including
03/08/2021 14:09
Aug 3 (Reuters) - Axim Biotechnologies Inc AXIM.PK :
* AXIM® BIOTECHNOLOGIES TO ACQUIRE TECHNOLOGY INCLUDING TWO
FDA-CLEARED 510(K)’S FOR DIAGNOSTIC TESTING OF DRY EYE DISEASE
Source text for Eikon: ID:nGNXbBYs4s
Further company coverage: AXIM.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Axim Biotechnologies
See all newsBrief: AXIM Biotechnologies Partners With Arizona State University To Determine Antibody Levels Against Covid-19
Brief: Axim Biotechnologies Inc Develops Next Generation Of Its Rapid Neutralizing Antibody Test For Covid-19
Brief: AXIM Biotechnologies To Acquire Technology Including
Brief: Axim® Biotechnologies Successfully Completes Point-Of-Care Clinical Trials On Its Rapid Covid-19 Neutralizing Antibody Test
Brief: Axim Biotechnologies Inc Says Filed A Provisional Patent For A First-In-Class Face Mask That Captures And Deactivates Sars-Cov-2